
Corcept Therapeutics Incorporated: shareholders and insiders
Price
$67.79
November 18, 2026Market cap $7.2B
What Ploutos Investor adds for Corcept Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
$3.3M
1 person
Sold on the market
$98M
11 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan93%
- The rest7%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $3.3M by 1 person·sold $91M by 11 people
- 2025: no buys, sold $7.1M by 4 people
- 2026: bought $3.3M by 1 person, sold $91M by 11 people
- Nov 13, 2026James N WilsonDirectorKind10b5-1
- Nov 13, 2026James N WilsonDirectorKind10b5-1
- Nov 13, 2026James N WilsonDirectorKind10b5-1
- Nov 13, 2026James N WilsonDirectorKind10b5-1
- Nov 10, 2026Daniel N Swisher JRDirectorKind10b5-1
- Nov 10, 2026Daniel N Swisher JRDirectorKind10b5-1
- Nov 10, 2026Daniel N Swisher JRDirectorKind10b5-1
- Nov 3, 2026Sean MaduckKind10b5-1
- Nov 3, 2026Sean MaduckKind10b5-1
- Nov 3, 2026Sean MaduckKind10b5-1
- Nov 2, 2026Sean MaduckKind10b5-1
- Nov 2, 2026Sean MaduckKind10b5-1
- Nov 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Nov 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Nov 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Oct 15, 2026James N WilsonDirectorKind10b5-1
- Oct 15, 2026James N WilsonDirectorKind10b5-1
- Oct 15, 2026James N WilsonDirectorKind10b5-1
- Oct 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Oct 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Oct 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Oct 2, 2026Roberto Wandenkolk VieiraPresident, OncologyKind10b5-1
- Oct 2, 2026Joseph Douglas LyonChief Accounting & Technology OfficerKind10b5-1
- Oct 2, 2026Joseph Douglas LyonChief Accounting & Technology OfficerKind10b5-1
- Oct 2, 2026Joseph Douglas LyonChief Accounting & Technology OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | James N WilsonDirector | 10b5-1 | 2,191 | $71.80 | $157.3K | Form 4 |
| Nov 13, 2026 | James N WilsonDirector | 10b5-1 | 7,221 | $72.87 | $526.2K | Form 4 |
| Nov 13, 2026 | James N WilsonDirector | 10b5-1 | 563 | $73.42 | $41.3K | Form 4 |
| Nov 13, 2026 | James N WilsonDirector | 10b5-1 | 25 | $74.28 | $1.9K | Form 4 |
| Nov 10, 2026 | Daniel N Swisher JRDirector | 10b5-1 | 1,100 | $14.08 | $15.5K | Form 4 |
| Nov 10, 2026 | Daniel N Swisher JRDirector | 10b5-1 | 400 | $10.50 | $4.2K | Form 4 |
| Nov 10, 2026 | Daniel N Swisher JRDirector | 10b5-1 | 1,500 | $74.07 | $111.1K | Form 4 |
| Nov 3, 2026 | Sean Maduck | 10b5-1 | 13.2K | $8.27 | $108.8K | Form 4 |
| Nov 3, 2026 | Sean Maduck | 10b5-1 | 8,617 | $82.02 | $706.8K | Form 4 |
| Nov 3, 2026 | Sean Maduck | 10b5-1 | 4,542 | $82.68 | $375.5K | Form 4 |
| Nov 2, 2026 | Sean Maduck | 10b5-1 | 11.8K | $8.27 | $97.9K | Form 4 |
| Nov 2, 2026 | Sean Maduck | 10b5-1 | 11.8K | $81.42 | $964.1K | Form 4 |
| Nov 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 8,333 | $21.63 | $180.2K | Form 4 |
| Nov 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 6,657 | $80.73 | $537.4K | Form 4 |
| Nov 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 1,676 | $81.52 | $136.6K | Form 4 |
| Oct 15, 2026 | James N WilsonDirector | 10b5-1 | 6,654 | $114.48 | $761.7K | Form 4 |
| Oct 15, 2026 | James N WilsonDirector | 10b5-1 | 3,046 | $115.39 | $351.5K | Form 4 |
| Oct 15, 2026 | James N WilsonDirector | 10b5-1 | 300 | $116.30 | $34.9K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 8,333 | $21.63 | $180.2K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 1,100 | $114.52 | $126.0K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 2,086 | $115.73 | $241.4K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | 10b5-1 | 5,147 | $116.59 | $600.1K | Form 4 |
| Oct 2, 2026 | Joseph Douglas LyonChief Accounting & Technology Officer | 10b5-1 | 3,357 | $13.56 | $45.5K | Form 4 |
| Oct 2, 2026 | Joseph Douglas LyonChief Accounting & Technology Officer | 10b5-1 | 5,833 | $19.26 | $112.3K | Form 4 |
| Oct 2, 2026 | Joseph Douglas LyonChief Accounting & Technology Officer | 10b5-1 | 4,446 | $115.70 | $514.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 26, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by CORT's officers and directors from 2005 up to November 17, 2025, 21 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 16 more, back to 2005
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.90%
- Ingalls & SnyderShare of class6.80%
- Joseph K. BelanoffShare of class6.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.90% | 9.61M | Oct 27, 20263 filings since Apr 23, 2025 | 13G/A | |
| Ingalls & Snyder | 6.80% | 7.26M | Apr 21, 20262 filings since Feb 21, 2025 | 13G/A | |
| Joseph K. Belanoff | 6.30% | 6.82M | Feb 14, 2025 | 13G/A |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-7.8%
- D.E. ShawIn the quarter+118%
- Bridgewater (Dalio)In the quarter+366%
- AQR CapitalIn the quarter+41%
- Citadel Advisors (Griffin)In the quarter+120%
- Millennium Mgmt (Englander)In the quarter+0.0%
- Glenview CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 4.85M | -7.8% | $559M | 0.76% |
| D.E. Shaw | 1.92M | +118% | $222M | 0.14% |
| Bridgewater (Dalio) | 268.2K | +366% | $31M | 0.13% |
| AQR Capital | 3.64M | +41% | $420M | 0.12% |
| Citadel Advisors (Griffin) | 239.8K | +120% | $28M | 0.02% |
| Millennium Mgmt (Englander) | 152.6K | +0.0% | $18M | 0.01% |
| Glenview Capital | 4,800 | $600.0K | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.07% of its shares outstanding were held short, +0.6% since the report before.
- Shares held short
- 8.59M
- 8.07%
- Since the report before8.54M on Sep 30, 2026
- +0.6%
- 12.3
- 698.6K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 14.12M
- Nov 15, 2023: Shares held short 15.27M
- Nov 30, 2023: Shares held short 15.38M
- Dec 15, 2023: Shares held short 15.26M
- Dec 29, 2023: Shares held short 15.39M
- Jan 12, 2024: Shares held short 15.67M
- Jan 31, 2024: Shares held short 19.32M
- Feb 15, 2024: Shares held short 19.64M
- Feb 29, 2024: Shares held short 19.86M
- Mar 15, 2024: Shares held short 20.22M
- Mar 28, 2024: Shares held short 21.33M
- Apr 15, 2024: Shares held short 21.12M
- Apr 30, 2024: Shares held short 19.80M
- May 15, 2024: Shares held short 19.80M
- May 31, 2024: Shares held short 19.29M
- Jun 14, 2024: Shares held short 21.25M
- Jun 28, 2024: Shares held short 21.88M
- Jul 15, 2024: Shares held short 22.75M
- Jul 31, 2024: Shares held short 22.26M
- Aug 15, 2024: Shares held short 21.59M
- Aug 30, 2024: Shares held short 22.09M
- Sep 13, 2024: Shares held short 21.71M
- Sep 30, 2024: Shares held short 21.51M
- Oct 15, 2024: Shares held short 20.68M
- Oct 31, 2024: Shares held short 18.80M
- Nov 15, 2024: Shares held short 18.34M
- Nov 29, 2024: Shares held short 17.05M
- Dec 13, 2024: Shares held short 15.72M
- Dec 31, 2024: Shares held short 15.96M
- Jan 15, 2025: Shares held short 16.26M
- Jan 31, 2025: Shares held short 15.81M
- Feb 14, 2025: Shares held short 15.39M
- Feb 28, 2025: Shares held short 16.04M
- Mar 14, 2025: Shares held short 16.33M
- Mar 31, 2025: Shares held short 16.53M
- Apr 15, 2025: Shares held short 12.29M
- Apr 30, 2025: Shares held short 13.18M
- May 15, 2025: Shares held short 12.48M
- May 30, 2025: Shares held short 12.64M
- Jun 13, 2025: Shares held short 12.65M
- Jun 30, 2025: Shares held short 11.45M
- Jul 15, 2025: Shares held short 11.22M
- Jul 31, 2025: Shares held short 11.05M
- Aug 15, 2025: Shares held short 10.59M
- Aug 29, 2025: Shares held short 10.88M
- Sep 15, 2025: Shares held short 10.81M
- Sep 30, 2025: Shares held short 10.64M
- Oct 15, 2025: Shares held short 10.24M
- Oct 31, 2025: Shares held short 11.05M
- Nov 14, 2025: Shares held short 10.17M
- Nov 28, 2025: Shares held short 10.34M
- Dec 15, 2025: Shares held short 10.11M
- Dec 31, 2025: Shares held short 9.15M
- Jan 15, 2026: Shares held short 8.19M
- Jan 30, 2026: Shares held short 9.28M
- Feb 13, 2026: Shares held short 10.04M
- Feb 27, 2026: Shares held short 12.47M
- Mar 13, 2026: Shares held short 13.03M
- Mar 31, 2026: Shares held short 12.45M
- Apr 15, 2026: Shares held short 11.34M
- Apr 30, 2026: Shares held short 10.71M
- May 15, 2026: Shares held short 9.32M
- May 29, 2026: Shares held short 8.79M
- Jun 15, 2026: Shares held short 8.57M
- Jun 30, 2026: Shares held short 8.64M
- Jul 15, 2026: Shares held short 9.44M
- Jul 31, 2026: Shares held short 9.82M
- Aug 14, 2026: Shares held short 9.70M
- Aug 31, 2026: Shares held short 9.40M
- Sep 15, 2026: Shares held short 9.35M
- Sep 30, 2026: Shares held short 8.54M
- Oct 15, 2026: Shares held short 8.59M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading49.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 49.6% of the shares in the reported trades were short sales, against 52.4% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 49.6%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 52.4%
- Change
- -2.8 pts
- Short sales a dayon average, of 554.9K shares
- 275.0K
- More than atof 3,659 US-listed companies, same days
- 47%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 57.1%
- Oct 12, 2026: Short sales 41.8%
- Oct 13, 2026: Short sales 45.8%
- Oct 14, 2026: Short sales 60%
- Oct 15, 2026: Short sales 55%
- Oct 16, 2026: Short sales 41.6%
- Oct 19, 2026: Short sales 46.2%
- Oct 20, 2026: Short sales 52%
- Oct 21, 2026: Short sales 44.9%
- Oct 22, 2026: Short sales 48%
- Oct 23, 2026: Short sales 58.6%
- Oct 26, 2026: Short sales 57.9%
- Oct 27, 2026: Short sales 41.6%
- Oct 28, 2026: Short sales 49.7%
- Oct 29, 2026: Short sales 52.2%
- Oct 30, 2026: Short sales 47.1%
- Nov 2, 2026: Short sales 46.1%
- Nov 3, 2026: Short sales 45.5%
- Nov 4, 2026: Short sales 54.2%
- Nov 5, 2026: Short sales 42.6%
- Nov 6, 2026: Short sales 60.9%
- Nov 9, 2026: Short sales 46.8%
- Nov 10, 2026: Short sales 59.1%
- Nov 11, 2026: Short sales 46.2%
- Nov 12, 2026: Short sales 40.1%
- Nov 13, 2026: Short sales 36.7%
- Nov 16, 2026: Short sales 59.2%
- Nov 17, 2026: Short sales 52.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Joseph K BelanoffChief Executive OfficerDirectly–
- James N WilsonDirectorDirectly376.8K
- David L MahoneyDirectorDirectly3,523
- G Leonard Baker JrDirectorDirectly1.12M
- Sean MaduckSee RemarksDirectly119.7K
- Gary Charles RobbChief Business OfficerDirectly55.2K
- Atabak MokariChief Financial OfficerDirectly16.3K
- Joseph Douglas LyonSee RemarksDirectly5,683
- William GuyerChief Development OfficerDirectly3,526
- Roberto Wandenkolk VieiraPresident, OncologyDirectly3,946
- Kimberly ParkDirectorDirectly–
- Daniel N Swisher JRDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Joseph K BelanoffChief Executive Officer | – | 2.57M | Jun 1, 2026 | Form 4 |
| James N WilsonDirector | 376.8K | 1.07M | Nov 13, 2026 | Form 4 |
| David L MahoneyDirector | 3,523 | 1.23M | Aug 18, 2026 | Form 4 |
| G Leonard Baker JrDirector | 1.12M | – | Mar 17, 2026 | Form 4 |
| Sean MaduckSee Remarks | 119.7K | – | Nov 3, 2026 | Form 4 |
| Gary Charles RobbChief Business Officer | 55.2K | 39.7K | Sep 24, 2026 | Form 4 |
| Atabak MokariChief Financial Officer | 16.3K | – | Sep 2, 2026 | Form 4 |
| Joseph Douglas LyonSee Remarks | 5,683 | – | Oct 2, 2026 | Form 4 |
| William GuyerChief Development Officer | 3,526 | 787 | Sep 1, 2026 | Form 4 |
| Roberto Wandenkolk VieiraPresident, Oncology | 3,946 | – | Nov 2, 2026 | Form 4 |
| Kimberly ParkDirector | – | – | Aug 26, 2026 | Form 4 |
| Daniel N Swisher JRDirector | – | – | Nov 10, 2026 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund1.90%
- IJTiShares S&P Small-Cap 600 Growth ETFWeight in the fund0.91%
- PPHVanEck Pharmaceutical ETFWeight in the fund0.50%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.45%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.45%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.23%
- IWPiShares Russell Mid-Cap Growth ETFWeight in the fund0.23%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.22%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.20%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.18%
31 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 430
- Q4 2025: Managers 390
- Q1 2026: Managers 354
- Q2 2026: Managers 424
Institutional investors by quarter
The fund managers holding CORT, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 424 managers held 82.39M shares, worth $7.2B. During the quarter 128 opened a position, 58 closed one, 142 added and 108 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+2.3%
- Ingalls & SnyderIn the quarter+4.3%
- Renaissance TechnologiesIn the quarter-7.4%
- Vanguard Portfolio ManagementIn the quarter+4.6%
- Vanguard Capital ManagementIn the quarter+2.3%
- Parallel AdvisorsIn the quarter-0.4%
- FMRIn the quarter+4.6%
- State StreetIn the quarter+2.5%
- AQR CapitalIn the quarter+536%
- Geode Capital ManagementIn the quarter-6.7%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 12.43M | +2.3% | $1.1B |
| Ingalls & Snyder | 7.93M | +4.3% | $690M |
| Renaissance Technologies | 5.26M | -7.4% | $457M |
| Vanguard Portfolio Management | 5.04M | +4.6% | $439M |
| Vanguard Capital Management | 4.17M | +2.3% | $363M |
| Parallel Advisors | 3.96M | -0.4% | $345M |
| FMR | 3.34M | +4.6% | $290M |
| State Street | 3.28M | +2.5% | $285M |
| AQR Capital | 2.58M | +536% | $225M |
| Geode Capital Management | 2.53M | -6.7% | $220M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Corcept Therapeutics's filings show?
Who buys and sells is one part of Corcept Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CORT's insiders bought or sold?
From May 26, 2026 to Nov 17, 2026 Corcept Therapeutics's insiders bought 0 and sold $84M of shares on the market. 92% of the sales were under set 10b5-1 plans.
Which well-known managers hold CORT?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $559M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.